# Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

> **NCT02450136** · NA · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** pazopanib

## Key facts

- **NCT ID:** NCT02450136
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-08
- **Primary completion:** 2017-07-30
- **Final completion:** 2018-02
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450136, "Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02450136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*